Updated Date: Wed, 29 Mar 2023 00:00:00 EDT

Company disappointed by institute’s failure to recommend thyroid cancer therapy for specific patient group

Individual receives AVA6000 treatment as part of additional dose escalating study

Study becomes the first-in-human clinical trial involving OMX-0407 in a specific patient group

Funds will be used to ensure the wider pan-sarcoma development of lead candidate uPARAP

Updated Date: Mon, 27 Mar 2023 00:00:00 EDT

Five vital new appointments made to regulator’s insight, perspective and advice group

Study demonstrated a reduction in viral replication in the upper respiratory tract as well as influenza infection

Naloxone — a fast-acting opioid antidote — has saved lives, but it’s less effective against powerful synthetic opioids, […]

A novel drug is showing promise for alleviating both heart failure and the sleep apnea associated with it.